Entera Bio is a leader in the development of orally delivered peptides. Entera is collaborating with leading researchers in orthopedics and sports medicine to contribute its proprietary oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism. EB613 is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD.